Temomedac 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
IB/0036 
C.I.2.a - Change in the SPC, Labelling or PL of a 
25/03/2022 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
amended 
on 
SmPC, 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IB/0035/G 
This was an application for a group of variations. 
01/09/2020 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
IA/0034 
B.III.2.b - Change to comply with Ph. Eur. or with a 
06/08/2020 
n/a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
IB/0033 
C.I.2.a - Change in the SPC, Labelling or PL of a 
21/07/2020 
19/10/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0032 
C.I.z - Changes (Safety/Efficacy) of Human and 
30/03/2020 
19/10/2020 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
Page 2/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0031 
C.I.z - Changes (Safety/Efficacy) of Human and 
20/09/2019 
19/10/2020 
SmPC 
Veterinary Medicinal Products - Other variation 
IA/0030 
A.4 - Administrative change - Change in the name 
17/07/2019 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IA/0029/G 
This was an application for a group of variations. 
07/09/2018 
n/a 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
Page 3/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
exist per material) 
IB/0028 
C.I.2.a - Change in the SPC, Labelling or PL of a 
01/06/2018 
12/06/2019 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0027 
B.II.e.3.c - Change in test procedure for the 
22/02/2018 
n/a 
immediate packaging of the finished product - 
Deletion of a test procedure if an alternative test 
procedure is already authorised 
IB/0025/G 
This was an application for a group of variations. 
20/07/2017 
n/a 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
IAIN/0026 
C.I.z - Changes (Safety/Efficacy) of Human and 
14/07/2017 
02/08/2018 
SmPC, 
Page 4/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
IAIN/0024/G 
This was an application for a group of variations. 
27/04/2017 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.III.2.a.1 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
II/0022 
B.I.z - Quality change - Active substance - Other 
04/08/2016 
n/a 
variation 
IA/0023/G 
This was an application for a group of variations. 
22/07/2016 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
Page 5/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
IB/0021 
C.I.2.a - Change in the SPC, Labelling or PL of a 
14/07/2015 
22/07/2016 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IAIN/0020 
A.1 - Administrative change - Change in the name 
09/09/2014 
28/07/2015 
SmPC, Annex 
and/or address of the MAH 
II, Labelling 
and PL 
IB/0019 
Update of section 4.8 of the SmPC in order to include 
21/08/2014 
28/07/2015 
SmPC, 
the calculated frequency of hepatic related disorders. 
The Package Leaflet was updated accordingly. In 
addition, the MAH proposed changes to the minimum 
particulars to appear on small immediate packaging. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
Labelling and 
PL 
Page 6/12 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
R/0018 
Renewal of the marketing authorisation. 
22/05/2014 
18/07/2014 
SmPC and PL 
Based on the review of the available information, the CHMP 
is of the opinion that the quality, the safety and the efficacy 
of this medicinal product continues to be adequately and 
sufficiently demonstrated and therefore considers the 
benefit/risk profile of Temomedac continues to be 
favourable. 
The CHMP is also of the opinion that the renewal can be 
granted with unlimited validity. 
IB/0017 
C.I.2.a - Change in the SPC, Labelling or PL of a 
21/01/2014 
31/03/2014 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IAIN/0016 
B.II.d.1.h - Change in the specification parameters 
09/12/2013 
n/a 
and/or limits of the finished product - Update of the 
dossier to comply with the provisions of an updated 
general monograph of the Ph. Eur. for the finished 
product 
IB/0015 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/04/2013 
31/03/2014 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
II and PL 
Page 7/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0012/G 
This was an application for a group of variations. 
20/02/2013 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or supplier of the 
AS, starting material, reagent or intermediate used 
in the manufacture of the AS 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.a.3.z - Change in batch size (including batch size 
ranges) of AS or intermediate - Other variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
IA/0014 
B.III.1.b.3 - Submission of a new or updated Ph. Eur. 
15/02/2013 
n/a 
TSE Certificate of suitability - Updated certificate 
from an already approved manufacturer 
Page 8/12 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0013/G 
This was an application for a group of variations. 
15/02/2013 
n/a 
B.II.a.1.a - Change or addition of imprints, bossing 
or other markings including replacement, or addition 
of inks used for product marking - Changes in 
imprints, bossing or other markings 
B.III.1.b.2 - Submission of a new or updated Ph. Eur. 
TSE Certificate of suitability - New certificate for a 
starting material/reagent/intermediate/or excipient 
from a new or an already approved manufacturer 
B.III.1.b.3 - Submission of a new or updated Ph. Eur. 
TSE Certificate of suitability - Updated certificate 
from an already approved manufacturer 
IB/0011 
C.I.z - Changes (Safety/Efficacy) of Human and 
05/09/2012 
25/10/2012 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
IA/0010/G 
This was an application for a group of variations. 
20/08/2012 
n/a 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
IB/0007/G 
This was an application for a group of variations. 
13/10/2011 
n/a 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
Page 9/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.f.1.d - Stability of FP - Change in storage 
conditions of the finished product or the 
diluted/reconstituted product 
IA/0008 
B.II.d.2.a - Change in test procedure for the finished 
05/10/2011 
n/a 
product - Minor changes to an approved test 
procedure 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
03/10/2011 
n/a 
SmPC, 
To update section 4.8 of the SMPC to include information 
generic/hybrid/biosimilar products following 
Labelling and 
on possible risk of hepatotoxicity associated with 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
PL 
Temozolomid identified following a cumulative review. The 
PL is updated accordingly.  Additionally, formal and 
linguistic changes indicated in the translations of the 
reference product information were introduced.  
Furthermore, the PILs for the different strenghts are 
combined in line with texts for reference product. 
IA/0006/G 
This was an application for a group of variations. 
27/07/2011 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer of the finished 
product, including quality control sites (excluding 
manufacturer for batch release) 
B.III.1.b.2 - Submission of a new or updated Ph. Eur. 
TSE Certificate of suitability - New certificate for a 
starting material/reagent/intermediate/or excipient 
from a new or an already approved manufacturer 
B.III.1.b.3 - Submission of a new or updated Ph. Eur. 
TSE Certificate of suitability - Updated certificate 
from an already approved manufacturer 
Page 10/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0005 
C.I.9.i - Changes to an existing pharmacovigilance 
29/06/2011 
n/a 
Annex II 
system as described in the DDPS - Change(s) to a 
DDPS following the assessment of the same DDPS in 
relation to another medicinal product of the same 
MAH 
IB/0004/G 
This was an application for a group of variations. 
21/05/2010 
n/a 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.2.a - Change to batch release arrangements 
and quality control testing of the FP - Replacement 
or addition of a site where batch control/testing 
takes place 
B.II.b.3.a - Change in the manufacturing process of 
the finished product - Minor change in the 
manufacturing process of an immediate release solid 
oral dosage form or oral solutions 
IB/0003 
C.I.8.b - Introduction of a new Pharmacovigilance 
21/05/2010 
n/a 
Annex II 
system - which has been assessed by the relevant 
NCA/EMA for another product of the same MAH 
IA/0002/G 
This was an application for a group of variations. 
27/04/2010 
n/a 
Annex II and 
PL 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
Page 11/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
site 
B.II.b.2.b.2 - Change to batch release arrangements 
and quality control testing of the FP - Including batch 
control/testing 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
T/0001 
Transfer of Marketing Authorisation 
24/02/2010 
26/03/2010 
SmPC, 
Transfer of Marketing Authorisation Holder from Alfred E. 
Labelling and 
Tiefenbacher GmbH & Co. KG to Medac GmbH. 
PL 
Page 12/12 
 
 
 
 
 
 
 
 
